Interventional Oncology Devices | Europe | 2017 | Market Analysis

The European market for interventional oncology devices is an evolving landscape characterized by vast differences in regional trends, rapid cannibalization of RF ablation by microwave ablation, new emerging technologies, strategic acquisitions, and strong competition between different embolization treatments.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in Europe across a 10-year period.

Ablation therapy procedure volumes continue to grow for liver, lung, and kidney cancer while novel indications such as bone, pancreatic, and prostate cancer represent growth opportunities in the interventional oncology market.

What are the advantages and disadvantages of each type of ablation device offered by competitors and how do these differences affect adoption for different indications?

What are the major demographic, economic, and local trend differences across Europe that impact the adoption of these devices?

Microwave ablation devices are growing in popularity among interventional oncologists, and newer technologies, such as cryoablation and IRE, are also being adopted.

What are the advantages and disadvantages of each type of ablation device?

How does the uptake of microwave ablation devices affect other types of ablation devices, like RF ablation devices, and how are competitors preparing for this shift?

In which indications will these newer ablation devices experience the fastest adoption?

How can companies in the fragmented microwave ablation market gain a competitive advantage?

Radioembolization beads continue to represent the largest segment of the embolization market, although the microsphere and DEB markets will experience strong growth over the forecast period.

How will factors such as the recent SIRFLOX trial and regional variance in reimbursement and physician preferences contribute to the adoption of different embolics for the treatment of both primary and secondary liver cancer?

What are the latest embolization particle innovations and what implications are associated with these advances?